
    
      Healthy subjects are enrolled once they have been screened and it is determined they qualify.
      The subjects are randomized to either placebo or the dose of teduglutide as outlined by the
      protocol at a 1:3 ratio. They will be injected with investigational product for eight
      consecutive days, with measurements taken including safety.
    
  